Menu
  • Join
  • Login
  • Contact
 

Search abstracts


DEVELOPMENT RESEARCH USING DRUG DISCOVERY TOOLS AND LARGE-SCALE MEDICAL INFORMATION

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: ZAMAMI, Yoshito (Tokushima University Graduate School of Biomedical Sciences, Clinical Pharmacology and Therapeutics, Japan)
  • Co-author(s): Yoshito Zamami: Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan;Pharmacy, Tokushima University Hospital, Tokushima, Japan
    Yuki Izawa-Ishizawa: AWA Support Center, Tokushima University, Tokushima, Japan
    Takahiro Niimura: Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Mitsuhiro Goda: Pharmacy, Tokushima University Hospital, Tokushima, Japan
    Naoto Okada: Pharmacy, Tokushima University Hospital, Tokushima, Japan
    Kenshi Takechi: Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan
    Masayuki Chuma: Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan
    Keijo Fukushima: Pharmacology for Life Sciences, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Yuya Horinouchi: Pharmacology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Yasumasa Ikeda: Pharmacology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Hiromichi Fujino: Pharmacology for Life Sciences, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Koichiro Tsuchiya: Medical Pharmacology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
    Keisuke Ishizawa: Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan;Pharmacy, Tokushima University Hospital, Tokushima, Japan
  • Abstract:

    Background

    Oxaliplatin causes oxaliplatin-induced peripheral neuropathy (OIPN) as a side effect that reduces the patient's quality of life.Therefore, the development of preventive agents against OIPN is an Important research area.

    Methods

    We searched for candidate drugs that counteract changes in gene expression related to OIPN using LINCS, a drug

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses